Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML-Reference-Cited by-同舟云学术

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

Published:2015-07-21 Issue:8 Volume:90 Page:732-736
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

DiNardo Courtney D.¹,Ravandi Farhad¹,Agresta Sam²,Konopleva Marina¹,Takahashi Koichi¹,Kadia Tapan¹,Routbort Mark³,Patel Keyur P.³,Mark Brandt ¹,Pierce Sherry¹,Garcia-Manero Guillermo¹,Cortes Jorge¹,Kantarjian Hagop¹

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Agios Pharmaceuticals; Cambridge Massachusetts

3. Department of Hematopathology; The University of Texas MD Anderson Cancer Center; Houston Texas

Funder

CCSG

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24072/fullpdf

Reference31 articles.

1. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate;Ward;Cancer Cell,2010

2. Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism;Reitman;J Natl Cancer Inst,2010

3. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability;Wise;Proc Natl Acad Sci USA,2011

4. IDH mutation impairs histone demethylation and results in a block to cell differentiation;Lu;Nature,2012

5. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation;Figueroa;Cancer Cell,2010

Cited by 248 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies;Cells;2024-08-21

2. Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia;Biomedicines;2024-08-06

3. Influence of genetic co‐mutation on chemotherapeutic outcome in NPM1‐mutated and FLT3‐ITD wild‐type AML patients;Cancer Medicine;2024-08

4. Traditional Chinese medicine for acute myelocytic leukemia therapy: exploiting epigenetic targets;Frontiers in Pharmacology;2024-06-04

5. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia;Expert Review of Hematology;2024-05-21